Vivian Y. Shi: On the board of directors for the Hidradenitis Suppurativa Foundation (HSF), advisor for the National Eczema Association, shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from AbbVie, Altus Lab/cQuell, Alumis, Aristea Therapeutics, Boehringer Ingelheim, Burt’s Bees, Dermira, Eli Lilly and Company, Galderma, Genentech, GpSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Technology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, Sun Pharma, Target-PharmaSolutions and UCB. John R. Ingram: Received a stipend as immediate past-Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. Consultant for AbbVie, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Engitix, Incyte, Insmed, Kymera Therapeutics, MoonLake Immunotherapeutics, Novartis, UCB, UNION Therapeutics and Viela Bio. Co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS and department receives income from copyright of the Dermatology Life Quality Index (DLQI) and related instruments. Affiliated with the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany. Hadar Lev-Tov: Consultant for Novartis and UCB. Sylke Schneider-Burrus: Received honoraria for participation in advisory boards, in clinical trials, and/or as speaker from AbbVie, Biogen, Boehringer Ingelheim, Hexal, MoonLake Immunotherapeutics, Novartis, Sanofi and UCB. Seth Forman: Investigator/consultant and/or advisor to AbbVie, Aclaris, Almirall, Arcutis, ASLAN Pharmaceuticals, BioHaven, Boehringer Ingelheim, Bristol Myers Squibb, Cali, Concert, Eli Lilly and Company, Evelo, Horizon Therapeutics, Incyte, Janssen, Merck, Pfizer, UCB and Vertex. Martina L. Porter: Consultant and investigator for AbbVie, Avalo Therapeutics, Aristea, Eli Lilly and Company, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics and UCB; consultant for Alumis, FIDE, Trifecta Clinical/WCG and ZuraBio; investigator for Anaptys Bio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals and Regeneron; received royalties from Beth Israel Deaconess Medical Center. Koremasa Hayama: Principal investigator for and consultancy/advisory boards from AbbVie, Boehringer Ingelheim and Novartis; speaker fees/grants from AbbVie, Boehringer Ingelheim, Eisai, Novartis and UCB. Linnea Thorlacius: Co‑copyright holder of HIDE© (HIdradenitis suppurativa DrainagE), HiSQOL© (Hidradenitis Suppurativa Quality of Life) and HS-IGA© (Hidradenitis Suppurativa Investigator Global Assessment). Investigator for Incyte, Janssen, Novartis and UCB. Speaker fees from UCB. Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert L. Rolleri: Employees and shareholders of UCB. Jacek C. Szepietowski: Consultant and advisory board member of AbbVie, LEO Pharma, Novartis, Pierre Fabre, Sanofi-Genzyme, UCB, Sandoz, Almirall, Boehringer Ingelheim and Galderma; speaker for AbbVie, Almirall, Boehringer Ingelheim, Janssen, Eli Lilly and Company, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi Genzyme and UCB; investigator for AbbVie, Acelyrin, Almirall Hermal, Amgen, AnaptysBio, Argenx, Aslan, Boehringer Ingelheim, Biocom, Bio Thera, Bristol Myers Squibb, Celltrion, CuraTeQ Biologics, DICE Therapeutics, Eli Lilly and Company, Helm AG, Galapagos, Galderma, Janssen, Incyte, InflaRX, Kiniksa, Kymab Limited, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, Moonlake, Novartis, Pierre Fabre, Pfizer, Regeneron Pharmaceuticals, Takeda, Teva, Trevi Therapeutics, UCB, Uni Therapeutics and Ventyx Bioscience; editorial board member of Dermatology and Therapy; was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Affiliated with the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany.

The study protocol, amendments and patient informed consent were reviewed by a national, regional or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)–Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Ethics approval was obtained from the relevant institutional review boards at participating sites. BE HEARD I&II have previously been published and full ethical approval was acquired for both of these studies. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.